News Conference News TCT 2025 LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI L.A. McKeown October 27, 2025
News Conference News AHA 2023 Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH Caitlin E. Cox November 12, 2023
News Conference News TCT 2023 LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI L.A. McKeown October 25, 2023
News Conference News TCT 2023 Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door? L.A. McKeown October 24, 2023
News Conference News EAS 2023 Newest Resorbable Magnesium Scaffold Shows Promise in BIOMAG-1 Michael O'Riordan May 25, 2023
News Conference News TCT 2021 Good Long-term Results With FANTOM BVS, but More Data Needed Michael O'Riordan October 21, 2021
News Conference News AHA 2020 Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT Todd Neale November 15, 2020
News Conference News WRAP IT: Novel Antibacterial ‘Envelope’ Reduces Rate of Infections From Implanted Cardiac Devices L.A. McKeown March 17, 2019
News Conference News AHA 2018 TiCAB: Ticagrelor No Help for Preventing Graft Failure Post-CABG Shelley Wood November 13, 2018
News Conference News TCT 2018 Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials Michael O'Riordan September 25, 2018
News Conference News TCT 2018 TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More Shelley Wood September 17, 2018
News Conference News ESC 2018 Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients Michael O'Riordan August 28, 2018
News Conference News ACC 2018 Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues Michael O'Riordan March 11, 2018
News Conference News TCT 2017 Long-term Absorb BVS Data Continue to Disappoint Michael O'Riordan October 31, 2017
News Conference News TCT 2017 TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More Shelley Wood October 20, 2017
News Conference News EuroPCR 2017 DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit Michael O'Riordan May 16, 2017
News Conference News ACC 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
News Conference News ACC 2017 FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS Michael O'Riordan March 18, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News CRT 2017 Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate Michael O'Riordan February 21, 2017